ADMA Biologics

108 articles with ADMA Biologics

• ADMA Biologics Announces Presentation on Respiratory Viral Infections and New Data on S. Pneumoniae at IDWeek 2020

  10/21/2020

  ADMA Biologics, Inc. announced an exclusive educational event at IDWeek 2020 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Lisa Forbes Satter from Baylor College of Medicine and Texas Children’s Hospital, as well as new data on Streptococcus pneumonia in an on-demand poster session.

• ADMA Biologics to Participate in Morgan Stanley Virtual Healthcare Conference - Sep 09, 2020

  9/9/2020

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Virtual Healthcare Conference on Monday, September 14, 2020, at 4:30 p.m. ET.

• 

  Biopharma Update on the Novel Coronavirus: September 4

  9/4/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.

• ADMA Biologics Highlights Launch of COVID-19 ImmunoRank™ Neutralization MICRO-ELISA Assay to Detect SARS-CoV-2 Neutralizing Antibodies in Plasma

  9/3/2020

  ImmunoRank Offers a Faster, Simpler, More Cost Effective Way to Identify High Titer Convalescent Plasma for Use in Both Treating COVID-19 Patients and for Creating COVID-19 Hyperimmune Globulins

• ADMA Biologics to Participate in Upcoming Investor Conferences - Sep 02, 2020

  9/2/2020

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that Adam Grossman, President and Chief Executive Officer, is scheduled to participate in the following upcoming investor conferences in September

• ADMA Biologics Reports Business Highlights and Second Quarter 2020 Financial Results

  8/5/2020

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, reported business highlights and financial results for its fiscal second quarter and six months ended June 30, 2020, and provided an overview of recent progress and accomplishments.

• ADMA Biologics to Report Business Highlights and Second Quarter 2020 Financial Results on August 5, 2020Conference Call Scheduled for Wednesday, August 5, 2020, at 4:30 p.m. ET

  7/29/2020

  ADMA Biologics, Inc. announced the Company will host a live conference call and audio webcast on Wednesday, August 5, 2020 at 4:30 p.m. ET, to discuss its business highlights and financial results for the second quarter ended June 30, 2020.

• ADMA Biologics Opens Its Newest ADMA BioCenters Plasma Collection Facility

  7/6/2020

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commencement of operations and initiation of collections at its newest ADMA BioCenters plasma collection facility located in Knoxville, TN.

• ADMA Biologics Announces Martha J. Demski Elected to Board of Directors

  6/23/2020

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that the proposed resolution to elect Martha J. Demski to its Board of Directors was approved at the Company’s recent Annual Shareholder Meeting, held June 18, 2020.

• ADMA Biologics to Participate in Jefferies 2020 Virtual Healthcare Conference

  5/27/2020

  ADMA Biologics, Inc. announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 2:00 p.m. ET.

• 

  Biopharma Update on the Novel Coronavirus: May 21

  5/21/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.

• ADMA Biologics Commences Collection of COVID-19 Plasma from Recovered Patients

  5/21/2020

  ADMA Biologics, Inc., announced it has commenced the collection of convalescent plasma through its wholly-owned subsidiary, ADMA BioCenters Georgia Inc., from individuals who have recovered from COVID-19.

• 

  Biopharma Update on the Novel Coronavirus: May 8

  5/8/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.

• ADMA Biologics Provides Corporate Update on Supply Chain Robustness and Recent Accomplishments

  5/7/2020

  ADMA Biologics, Inc. announced several recent corporate achievements pertaining to its supply chain robustness objectives as established at the beginning of 2020.

• ADMA Biologics Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress

  5/6/2020

  ADMA Biologics, Inc. reported financial results for the quarter ended March 31, 2020, ADMA’s first fiscal quarter, and provided an overview of recent progress and accomplishments.

• ADMA Biologics to Report First Quarter 2020 Financial Results on May 6, 2020Conference Call Scheduled for Wednesday, May 6, 2020, at 4:30 p.m. ET

  4/29/2020

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, announced that it will report financial results for the first quarter ended March 31, 2020 on Wednesday, May 6, 2020 after the U.S. financial markets close.

• ADMA Biologics Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress

  3/12/2020

  ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of recent progress and accomplishments.

• ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020Conference Call Scheduled for Thursday, March 12, 2020, at 4:30 p.m. ET

  3/5/2020

  ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), today announced that it will report financial results for the fourth quarter and full year ending December 31, 2019 on Thursday, March 12, 2020 after the U.S. financial markets close

• ADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections

  3/3/2020

  ADMA Biologics (“ADMA”), today announced that it has received another Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its intellectual property portfolio encompassing immunoglobulin plasma pool compositions used in the manufacturing of ASCENIV™

• ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock

  2/24/2020

  ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), today announced the closing of the issuance of an additional 3,525,000 shares of its common stock at a public offering price of $3.50 per share